Evoke Pharma Inc. (NASDAQ:EVOK) saw an uptick in trading volume on Thursday . 23,999,608 shares traded hands during mid-day trading, an increase of 881% from the previous session’s volume of 2,446,293 shares.The stock last traded at $3.15 and had previously closed at $2.05.

Several research firms recently weighed in on EVOK. Rodman & Renshaw downgraded Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research note on Monday, July 18th. Brean Capital cut Evoke Pharma from a “buy” rating to a “hold” rating in a report on Monday, July 18th. FBR & Co reiterated a “buy” rating on shares of Evoke Pharma in a report on Friday, July 8th. Finally, Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. Evoke Pharma presently has an average rating of “Hold” and a consensus price target of $13.34.

The firm’s market cap is $21.94 million. The stock has a 50 day moving average of $5.90 and a 200-day moving average of $4.73.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.